Samlyn Capital LLC Has $33.31 Million Stock Position in Natera, Inc. $NTRA

Samlyn Capital LLC reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 49.2% during the first quarter, Holdings Channel.com reports. The fund owned 235,572 shares of the medical research company’s stock after selling 227,784 shares during the period. Samlyn Capital LLC’s holdings in Natera were worth $33,312,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Fulton Bank N.A. lifted its stake in shares of Natera by 2.0% in the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company’s stock worth $516,000 after acquiring an additional 71 shares during the period. Compound Planning Inc. lifted its stake in Natera by 4.2% in the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company’s stock valued at $271,000 after buying an additional 78 shares during the period. QRG Capital Management Inc. lifted its stake in Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock valued at $766,000 after buying an additional 81 shares during the period. Earned Wealth Advisors LLC lifted its stake in Natera by 5.0% in the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company’s stock valued at $246,000 after buying an additional 82 shares during the period. Finally, Bridges Investment Management Inc. lifted its stake in Natera by 5.5% in the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company’s stock valued at $237,000 after buying an additional 87 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NTRA. Piper Sandler reissued an “overweight” rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Cowen reissued a “buy” rating on shares of Natera in a research report on Friday, August 8th. Stephens reissued an “overweight” rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Wall Street Zen cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Saturday, May 17th. One analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $194.00.

Insider Activity at Natera

In related news, Director Gail Boxer Marcus sold 4,299 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the sale, the director directly owned 8,118 shares of the company’s stock, valued at approximately $1,358,628.48. This represents a 34.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the sale, the director directly owned 6,015 shares of the company’s stock, valued at $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 55,344 shares of company stock valued at $8,271,610 over the last three months. 5.63% of the stock is currently owned by company insiders.

Natera Stock Up 0.9%

Shares of NASDAQ:NTRA opened at $168.02 on Friday. Natera, Inc. has a twelve month low of $110.57 and a twelve month high of $183.00. The stock’s 50 day moving average is $154.35 and its 200-day moving average is $153.91. The firm has a market capitalization of $23.06 billion, a price-to-earnings ratio of -87.97 and a beta of 1.68.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period in the previous year, the company earned ($0.30) earnings per share. Natera’s revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.